HP
MRSN

HealthInvest Partners’s Mersana Therapeutics MRSN Stock Holding History

HealthInvest Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,545
Closed -$765K – 39
2024
Q4 		$765K Hold
21,545
– – 0.36% 34
2024
Q3 		$1.02M Buy
21,545
+14,149
+191% +$624K 0.48% 33
2024
Q2 		$372K Buy
7,396
+3,396
+85% +$246K 0.23% 38
2024
Q1 		$448K Buy
+4,000
New +$398K 0.27% 44

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HealthInvest Partners's MRSN Position: Q1 2025 in Review

HealthInvest Partners sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 21,545 shares — an estimated $765K sold.

HealthInvest Partners first reported a position in MRSN in Q1 2024 and held it in 4 quarters. The position peaked at $1.02M in Q3 2024. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • HealthInvest Partners reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HealthInvest Partners sold 21,545 Mersana Therapeutics shares in Q1 2025, an estimated $765K.
  • HealthInvest Partners first reported a position in Mersana Therapeutics in Q1 2024 and held it in 4 quarters.
  • HealthInvest Partners's Mersana Therapeutics position peaked at $1.02M in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on HealthInvest Partners's 13F filing for Q1 2025, filed 5 May 2025.